|
| related topics |
| {product, market, service} |
| {product, liability, claim} |
| {product, candidate, development} |
| {acquisition, growth, future} |
| {competitive, industry, competition} |
| {personnel, key, retain} |
| {regulation, change, law} |
| {stock, price, operating} |
| {cost, regulation, environmental} |
| {operation, international, foreign} |
| {regulation, government, change} |
|
|
We Have More Indebtedness and Fewer Liquid Resources After the Acquisition of the Aesthetics Business of Laserscope, Which Could Adversely Affect Our Cash Flows and Business.
Although We Expect that Our Acquisition of the Aesthetics Business of Laserscope Will Result in Benefits to the Company, the Company May Not Realize Those Benefits Because of Integration and Other Challenges.
We Rely on Continued Market Acceptance of Our Existing Products and Any Decline in Sales of Our Existing Products Would Adversely Affect Our Business and Results of Operations.
Our Future Success Depends on Our Ability to Develop and Successfully Introduce New Products and New Applications
If We Cannot Increase Our Sales Volumes, Reduce Our Costs or Introduce Higher Margin Products to Offset Anticipated Reductions in the Average Unit Price of Our Products, Our Operating Results May Suffer.
We Are Exposed to Risks Associated With Worldwide Economic Slowdowns and Related Uncertainties.
If We Lose Key Personnel or Fail to Integrate Replacement Personnel Successfully, Our Ability to Manage Our Business Could Be Impaired
If We Fail to Maintain Our Relationships With Health Care Providers, Customers May Not Buy Our Products and Our Revenue and Profitability May Decline.
Our Stock Price Has Been and May Continue to be Volatile and an Investment in Our Common Stock Could Suffer a Decline in Value.
If We Fail to Comply With the FDA s Quality System Regulation and Laser Performance Standards, Our Manufacturing Operations Could Be Halted, and Our Business Would Suffer.
The Requirements of Complying with the Sarbanes-Oxley Act of 2002 Might Strain Our Resources, Which May Adversely Affect Our Business and Financial Condition.
Because We Do Not Require Training for Users of Our Products, and Sell Our Products to Non-physicians, There Exists an Increased Potential for Misuse of Our Products, Which Could Harm Our Reputation and Our Business.
Our Products Could Be Subject to Recalls Even After Receiving FDA Approval or Clearance. A Recall Would Harm Our Reputation and Adversely Affect Our Operating Results.
The Successful Outcome of Clinical Trials and the Development of New Applications Using Certain of Our Products will Accelerate Future Revenue Growth Rates.
Our Business is Subject to Environmental Regulations.
Full 10-K form ▸
|
|
| related documents |
| 943894--3/28/2008--EZENIA_INC |
| 810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
| 874734--3/8/2010--OSTEOTECH_INC |
| 25895--6/20/2007--CROWN_CRAFTS_INC |
| 834306--3/16/2006--BIOSITE_INC |
| 913616--3/12/2008--NATIONAL_DENTEX_CORP_/MA/ |
| 353569--2/26/2010--QUIDEL_CORP_/DE/ |
| 739944--3/11/2008--MEDTOX_SCIENTIFIC_INC |
| 739944--3/15/2007--MEDTOX_SCIENTIFIC_INC |
| 1009356--3/15/2007--SALIX_PHARMACEUTICALS_LTD |
| 739944--3/17/2006--MEDTOX_SCIENTIFIC_INC |
| 1006195--3/15/2007--MATRIXX_INITIATIVES_INC |
| 943894--3/24/2009--EZENIA_INC |
| 816284--2/20/2008--CELGENE_CORP_/DE/ |
| 736822--7/24/2008--IMMUCOR_INC |
| 739944--3/10/2009--MEDTOX_SCIENTIFIC_INC |
| 922612--8/14/2008--SCHMITT_INDUSTRIES_INC |
| 1009356--3/16/2006--SALIX_PHARMACEUTICALS_LTD |
| 943894--3/31/2010--EZENIA_INC |
| 785786--11/21/2007--PLEXUS_CORP |
| 882873--9/21/2009--UROLOGIX_INC |
| 890846--5/28/2010--UROPLASTY_INC |
| 862668--10/12/2010--ESCALON_MEDICAL_CORP |
| 1270597--3/23/2007--MERISANT_CO |
| 59527--2/25/2008--LINCOLN_ELECTRIC_HOLDINGS_INC |
| 874734--3/12/2008--OSTEOTECH_INC |
| 80035--4/7/2008--PREFORMED_LINE_PRODUCTS_CO |
| 25895--6/15/2006--CROWN_CRAFTS_INC |
| 80035--3/13/2009--PREFORMED_LINE_PRODUCTS_CO |
| 880432--9/28/2009--MISONIX_INC |
|